Thrombin-Activatable Fibrinolysis Inhibitor and Cardiovascular Risk Factors in Polycystic Ovary Syndrome

Abstract

Objective: We aimed to assess circulating thrombin activatable fibrinolysis inhibitor (TAFI) levels and carotid intima-media thickness (CIMT) in PCOS patients and control sujects. In this study we aimed to evaluate the relation between the levels of TAFI and homocysteine, high sensitive CRP (hsCRP), fibrinogen and CIMT in PCOS patients carrying a potential risk for developing CVD and diabetes and compared with age- and body mass index-matched controls.

Research Design and Methods: We studied 68 PCOS patients and 26 healthy controls. We conducted an observational study examining noninvasive markers of early CV disease in women with PCOS including structural CIMT. Noninvasive markers of early CVD, CIMT were measured in PCOS patients and control subjects. Metabolic parameters included fasting insulin and glucose levels, lipid and androgen levels, TAFI levels, hsCRP.

Results: Fasting glucose levels, prolactin, TSH, Total-cholesterol, LDL-cholesterol, triglyceride, estradiol, DHEA-S and age were similar in the two groups, whereas serum insulin, fibrinogen, hs-CRP, 17-OHP, free-testosterone, total testosterone, HOMA-IR, HDL were significantly elevated in PCOS patients in comparison to control subjects (p<0.05). Plasma TAFI levels were similarly in PCOS patients compared with healthy controls. No difference was observed in the combined IMT among the studied groups.

Conclusions: In our study, no significant difference in lipid parameters was determined between patients with PCOS and healthy controls. In our study, we did not observed any difference in CIMT measurements and TAFI levels between patients with PCOS and healthy controls that can be explained by their low ages and short duration of PCOS.

Key words

thrombin activatable fibrinolysis inhibitor - cardiovascular risk factors - polycystic ovary syndrome

References

• 1 Chang RJ. A practical approach to the diagnosis of polycystic ovary syndrome.  Am J Obstet Gynecol. 2004;  191 ((3)) 713-717
• 2 Legro R. Polycystic ovary syndrome and cardiovascular disease: a premature association?.  Endocr Rev. 2003;  24 302-312
• 3 Holte J, Gennarelli G, Wide L. et al . High prevalence of polycystic ovaries and associated clinical, endocrine, and metabolic features in women with previous gestational diabetes mellitus.  J Clin Endocrinol Metab. 1998;  83 1143-1150
• 4 Talbott E, Clerici A, Berga SL. et al . Adverse lipid and coronary heart disease risk profiles in young women with polycystic ovary syndrome: results of a case-control study.  J Clin Epidemiol. 1998;  51 415-422
• 5 Wild RA. Obesity, lipids, cardiovascular risk, and androgen excess.  Am J Med. 1995;  98 27S-32S
• 6 Diamanti-Kandarakis E, Spina G, Kouli C, Migdalis I. Increased endothelin-1 levels in women with polycystic ovary syndrome and the beneficial effect of metformin therapy.  J Clin Endocrinol Metab. 2001;  86:10 4666-4673
• 7 Kelly CC, Lyall H, Petrie JR. et al . Low grade chronic inflammation in women with polycystic ovary syndrome.  J Clin Endocrinol Metab. 2001;  86:6 2453-2455
• 8 Bajzar L, Manuel R, Nesheim ME. Purification and characterization of TAFI, a thrombinactivatable fibrinolysis inhibitor.  J Biol Chem. 1995;  270 14477-14484
• 9 Mosnier LO, Borne PA von dem, Meijers JCM, Bouma BN. Plasma TAFI levels influence the clot lysis time in healthy individuals in the presence of an intact intrinsic pathway of coagulation.  Thromb Haemost. 1998;  80 829-835
• 10 Aubert H, Frere C, Aillaud MF, Morange PE, Juhan-Vague I, Alessi MC. Weak and nonindependent association between plasma TAFI antigen levels and the insulin resistance syndrome.  J Thromb Haemost. 2003;  1 791-797
• 11 Kannel WB, D’Agostino RB, Wilson PWF, Belanger AJ, Gagnon DR. Diabetes, fibrinogen and risk of cardiovascular disease: the Framingham experience.  Am Heart J. 1990;  120 672-676
• 12 Wang W, Boffa MB, Bajzar L, Walker JB, Nesheim ME. A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activable fibrinolysis inhibitor.  J Biol Chem. 1998;  273 27176-27181
• 13 Hori Y, Gabazza EC, Yano Y, Katsuki A, Suzuki K, Adachi Y. et al . Insulin resistance is associated with increased circulating levels of thrombin-activatable fibrinolysis inhibitor in type 2 diabetic patients.  J Clin Endocrinol Metab. 2002;  87 660-665
• 14 Kruszynska YT, Yu JG, Olefsky JM, Sobel BE. Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects.  Diabetes. 2000;  49 633-639
• 15 Hamsten A, Faire U de, Walldius G, Dahlen G, Szamosi A, Landou C. et al . Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction.  Lancet. 1987;  8549 3-9
• 16 Colucci M, Binetti BM, Branca MG, Clerici C, Morelli A, Semeraro N, Gresele P. Deficiency of thrombin activatable fibrinolysis inhibitor in cirrhosis is associated with increased plasma fibrinolysis.  Hepatology. 2003;  38 230-237
• 17 The Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group . Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS).  Hum Reprod. 2004;  19 ((1)) 41-47
• 18 Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man.  Diabetologia. 1985;  28 412-419
• 19 Yarali H, Yildirir A, Aybar F, Kabakci G, Bukulmez O, Akgul E, Oto A. Diastolic dysfunction and increased serum homocysteine concentrations may contribute to increased cardiovascular risk in patients with polycystic ovary syndrome.  Fertil Steril. 2001;  76 ((3)) 511-516
• 20 Paradisi G, Steinberg HO, Hempfling A, Cronin J, Hook G, Shepard MK, Baron AD. Polycystic ovary syndrome is associated with endothelial dysfunction.  Circulation. 2001;  13:103 ((10)) 1410-1415
• 21 Kelly CJ, Speirs A, Gould GW, Petrie JR, Lyall H, Connell JM. Altered vascular function in young women with polycystic ovary syndrome.  J Clin Endocrinol Metab. 2002;  87 ((2)) 742-746
• 22 Kelly CC, Lyall H, Petrie JR, Gould GW, Connell JM, Sattar N. Low grade chronic inflammation in women with polycystic ovarian syndrome.  J Clin Endocrinol Metab. 2001;  86 ((6)) 2453-2455
• 23 Loverro G, Lorusso F, Mei L, Depalo R, Cormio G, Selvaggi L. The plasma homocysteine levels are increased in polycystic ovary syndrome.  Gynecol Obstet Invest. 2002;  53 ((3)) 157-162
• 24 Andersen P, Seljeflot I, Abdelnoor M, Arnesen H, Dale PO, Lovik A, Birkeland K. Increased insulin sensitivity and fibrinolytic capacity after dietary intervention in obese women with polycystic ovary syndrome.  Metabolism. 1995;  44 ((5)) 611-616
• 25 Tarkun I, Canturk Z, Arslan BC, Tureman E, Tarkun H. The plasminogen activator system in young and lean women with polycystic ovary syndrome.  Endocrinol J. 2004;  51 ((5)) 467-472
• 26 Muneyyirci-Delale O, Nacharaju VL, Dalloul M, Jalou S, Rahman M, Altura BM, Altura BT. Divalent cations in women with PCOS: implications for cardiovascular disease.  Gynecol Endocrinol. 2001;  15 ((3)) 198-201
• 27 Kelly CC, Lyall H, Petrie JR, Gould GW, Connell JM, Sattar N. Low grade chronic inflammation in women with polycystic ovarian syndrome.  J Clin Endocrinol Metab. 2001;  86 ((6)) 2453-2455
• 28 Santamaria A, Oliver A, Borrell M, Mateo J, Belvis R, Marti-Fabregas J, Ortin R, Tirado I, Souto JC, Fontcuberta J. Risk of ischemic stroke associated with functional thrombin-activatable fibrinolysis inhibitor plasma levels.  Stroke. 2003;  34 ((10)) 2387-2391
• 29 Leebeek FW, Goor MP, Guimaraes AH, Brouwers GJ, Maat MP, Dippel DW, Rijken DC. High functional levels of thrombin-activatable fibrinolysis inhibitor are associated with an increased risk of first ischemic stroke.  J Thromb Haemost. 2005;  3 ((10)) 2211-2218
• 30 Montaner J, Ribo M, Monasterio J, Molina CA, Alvarez-Sabin J. Thrombin-activable fibrinolysis inhibitor levels in the acute phase of ischemic stroke.  Stroke. 2003;  34 ((4)) 1038-1040
• 31 Silveira K, Schatteman F, Goossens E, Moor S, Scharpe M, Stromqvist . et al . Plasma procarboxypeptidase U in men with symptomatic coronary artery disease.  Thromb Haemost. 2000;  84 364-368
• 32 Schroeder V, Chatterjee T, Mehta H, Windecker S, Pham T, Devantay N. Thrombin activatable fibrinolysis inhibitor (TAFI) levels in patients with coronary artery disease investigated by angiography.  Thromb Haemost. 2002;  88 1020-1025
• 33 Zorio R, Castello C, Falco F, Espana A, Osa , Almenar L. et al . Thrombinactivatable fibrinolysis inhibitor in young patients with myocardial infarction and its relationship with the fibrinolytic function and the protein C system.  Br J Haematol. 2003;  122 958-965
• 34 Santamaria A, Martinez-Rubio A, Borrell M, Mateo J, Ortin R, Fontcuberta J. Risk of acute coronary artery disease associated with functional thrombin activatable fibrinolysis inhibitor plasma level.  Haematologica. 2004;  89 880-881
• 35 Juhan-Vague I, Morange PE, Aubert H, Henry M, Aillaud MF, Alessi MC. et al . Plasma thrombin-activatable fibrinolysis inhibitor antigen concentration and genotype in relation to myocardial infarction in the north and south of Europe.  Arterioscler Thromb Vasc Biol. 2002;  22 867-873
• 36 Paola Cellai A, Antonucci E, Alessandrello Liotta A, Fedi S, Marcucci R, Falciani M, Giglioli C, Abbate R, Prisco D. TAFI activity and antigen plasma levels are not increased in acute coronary artery disease patients admitted to a coronary care unit.  Thromb Res. 2005;  27 , [Epub ahead of print]
• 37 Santamaria A, Martinez-Rubio A, Borrell M, Mateo J, Ortin R, Fontcuberta J. Risk of acute coronary artery disease associated with functional thrombin activatable fibrinolysis inhibitor plasma level.  Haematologica. 2004;  89 ((7)) 880-881
• 38 Silveira A, Schatteman K, Goossens F, Moor E, Scharpé S, Strömqvist M, Hendriks D, Hamsten A. Plasma procarboxypeptidase U in men with symptomatic coronary artery disease.  Thromb Haemost. 2000;  84 364-368
• 39 Dahlgren E, Johansson S, Lindstedt G, Knutsson F, Oden A, Janson PO, Mattson LA, Crona N, Lundberg PA. Women with polycystic ovary syndrome wedge respected in 1956-1965: a long-term follow-up focusing on natural history and circulating hormones.  Fertil Steril. 1992;  57 ((3)) 505-513
• 40 Santamaria A, Borrell M, Oliver A, Ortin R, Forner R, Coll I, Mateo J, Souto JC, Fontcuberta J. Association of functional thrombin-activatable fibrinolysis inhibitor (TAFI) with conventional cardiovascular risk factors and its correlation with other hemostatic factors in a Spanish population.  Am J Hematol. 2004;  76 ((4)) 348-352
• 41 Schroeder V, Chatterjee T, Mehta H, Windecker S, Pham T, Devantay N, Meier B, Kohler HP. Thrombin activatable fibrinolysis inhibitor (TAFI) levels in patients with coronary artery disease investigated by angiography.  Thromb Haemost. 2002;  88 ((6)) 1020-1025
• 42 Wild S, Pierpoint T, McKeigue P, Jacobs H. Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study.  Clinical Endocrinology (Oxford). 2000;  52 595-600
• 43 Dahlgren E, Johansson S, Lindstedt G. et al . Women with polycystic ovary syndrome wedge resected in 1956-1965: a long-term follow-up focusing on natural history and circulating hormones.  Fertility and Sterility. 1992;  57 505-513
• 44 Christian RC, Dumesic DA, Behrenbeck T. et al . Prevalence and predictors of coronary artery calcification in women with polycystic ovary syndrome.  J Clin Endocrinol Metab. 2003;  88 2562-2568
• 45 Talbott E, Zborowski JV, MacHugh-Pemu K. et al .Metabolic cardiovascular syndromeand its relationship to coronary calcification in women with polycystic ovarian syndrome. Presented at Third International Workshop on Insulin Resistance, New Orleans, LA 2003
• 46 Talbott EO, Zborowski JV, Rager JR. et al . Evidence for an association between metabolic cardiovascular syndrome and coronary and aortic calcification among women with polycystic ovary syndrome.  J Clin Endocrinol Metab. 2004;  89 5454-5461
• 47 Talbott EO, Guzick DS, Sutton-Tyrrell K. et al . Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middleaged women.  Arteriosclerosis Thrombosis and Vascular Biology. 2000;  20 ((11)) 2414-2421
• 48 Solomon CG, Hu FB, Dunaif A. et al . Menstrual cycle irregularity and risk for future cardiovascular disease.  J Clin Endocrinol Metab. 2002;  87 ((5)) 2013-2017
• 49 Hori Y, Gabazza EC, Yano Y, Katsuki A, Suzuki K, Adachi Y, Sumida Y. Insulin resistance is associated with increased circulating level of thrombin-activatable fibrinolysis inhibitor in type 2 diabetic patients.  J Clin Endocrinol Metab. 2002;  87 ((2)) 660-665
• 50 Yano Y, Kitagawa N, Gabazza EC, Morioka K, Urakawa H, Tanaka T, Katsuki A, Araki-Sasaki R, Hori Y, Nakatani K, Taguchi O, Sumida Y, Adachi Y. Increased plasma thrombin-activatable fibrinolysis inhibitor levels in normotensive type 2 diabetic patients with microalbuminuria.  J Clin Endocrinol Metab. 2003;  88 ((2)) 736-741
• 51 Aubert H, Frere C, Aillaud MF, Morange PE, Juhan-Vague I, Alessi MC. Weak and nonindependent association between plasma TAFI antigen levels and the insulin resistance syndrome.  J Thromb Haemost. 2003;  1 ((4)) 791-797
• 52 Alexandraki K, Protogerou AD, Papaioannou TG, Piperi C, Mastorakos G, Lekakis J, Panidis D, Diamanti-Kandarakis E. Early microvascular and macrovascular dysfunction is not accompanied by structural arterial injury in polycystic ovary syndrome.  Hormones (Athens). 2006;  5 ((2)) 126-136
• 53 Orio F, Palomba S, Cascella T, De Simone B, Di Biase S, Russo T, Labella D, Zullo F, Lombardi G, Colao A. Early impairment of endothelial structure and function in young normal-weight women with polycystic ovary syndrome.  J Clin Endocrinol Metab. 2004;  89 4588-4593
• 54 Vural B, Caliskan E, Turkoz E, Kilic T, Demirci A. Evaluation of metabolic syndrome frequency and premature carotid atherosclerosis in young women with polycystic ovary syndrome.  Hum Reprod 1. 2005;  20 ((9)) 2409-2413
• 55 Talbott E, Guzick D, Sutton-Tyrrell K, McHugh-Pemu K, Zborowski J, Remsberg K, Kuller L. Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women.  Arterioscler Thromb Vasc Biol. 2000;  20 2414-2421

Correspondence